Cancer epigenetics: A perspective on the role of DNA methylatiion in acquired endocrine resistence

Chinese Journal of Cancer

Volumn 30, Issue 11, 2011, Pages 749-756

  Trimarchi, Michael P ^a   Mouangsavanh, Mary ^a   Huang, Tim Hui Ming ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Endocrine resistance; Epigenetics; Methylation; Methylome profiling

Indexed keywords

AROMATASE INHIBITOR; AZACITIDINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GEMCITABINE; GLUTATHIONE TRANSFERASE P1; NUCLEAR RECEPTOR COREPRESSOR; OXALIPLATIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR INTERACTING PROTEIN 140; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR SNAIL; TRICHOSTATIN A; UVOMORULIN;

ABLATION THERAPY; ACQUIRED ENDOCRINE RESISTANCE; ARTICLE; BREAST CANCER; CANCER RELAPSE; CELL ADHESION; CELL FATE; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENDOCRINE DISEASE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HIGH THROUGHPUT SCREENING; HISTONE MODIFICATION; HUMAN; LOSS OF FUNCTION MUTATION; PREDICTION; PROGNOSIS; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA METHYLATION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION;

EID: 80355135172     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10128     Document Type: Article

References (46)

1. Esteller M. Epigenetics in cancer [J]. N Engl J Med, 2008,358 (11):1148-1159.
2. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis [J]. Cell Mol Life Sci, 2011,68(10):1681-1702.
3. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs [J]. Annu Rev Pharmacol Toxicol, 2009,49: 243-263.
4. Ferreri AJ, DellOro S, Capello D, et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas [J]. Br J Haematol, 2004,126(5):657-664.
5. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias [J]. Blood, 1998,92(11):4296-4307.
6. Strathdee G, MacKean MJ, Illand M, et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer [J]. Oncogene, 1999,18(14):2335-2341.
7. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer [J]. J Clin Oncol, 1984,2(10):1102-1109.
8. Berger SL. The complex language of chromatin regulation during transcription [J]. Nature, 2007,447(7143):407-412.
9. Chi P, Allis CD, Wang GG. Covalent histone modifications- miswritten, misinterpreted and mis-er ased in human cancers [J]. Nat Rev Cancer, 2010,10(7):457-469.
10. Portela A, Esteller M. Epigenetic modifications and human disease [J]. Nat Biotechnol, 2010,28(10):1057-1068.
11. Coolen MW, Stirzaker C, Song JZ, et al. Consolidation of the cancer genome into domains of repressive chromatin by long- range epigenetic silencing (LRES) reduces transcriptional plasticity [J]. Nat Cell Biol, 2010,12(3):235-246.
12. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer [J]. Nat Rev Cancer, 2009,9(9):631-643.
13. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer [J]. Annu Rev Med, 2011,62:233-247.
14. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-re sistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-ac tivated protein kinase [J]. J Clin Oncol, 2005,23(11):2469-2476.
15. Fan M, Yan PS, Hartman-Frey C, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant [J]. Cancer Res, 2006,66(24):11954-11966.
16. van Agthoven T, van Agthoven TL, Dekker A, et al. Induction of estrogen independence of ZR-75 -1 human breast cancer cells by epigenetic alterations [J]. Mol Endocrinol, 1994,8(11): 1474-1483.
17. Sharma D, Saxena NK, Davidson NE, et al. Restoration of tamoxifen sensitivity in estrogen receptor-ne gative breast cancer cells: tamoxifen-bo und reactivated ER recruits distinctive corepressor complexes [J]. Cancer Res, 2006,66 (12):6370-6378.
18. Hostetter CL, Licata LA, Keen JC. Timing is everything: order of administration of 5-az a 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity [J]. Cancer Lett, 2009,275(2):178-184.
19. Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha- negative breast cancer cells to tamoxifen [J]. Oncogene, 2004,23(9):1724-1736.
20. Antoniotti S, Maggiora P, Dati C, et al. Tamoxifen up-re gulates c-er bB-2 expression in oestrogen-re sponsive breast cancer cells in vitro [J]. Eur J Cancer, 1992,28(2-3):318-321.
21. Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer [J]. Cancer Res, 2004,64(22):8184-8192.
22. Badia E, Duchesne MJ, Semlali A, et al. Long-te rm hydroxytamoxifen treatment of an MCF-7- derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling [J]. Cancer Res, 2000,60 (15): 4130-4138.
23. Girault I, Bieche I, Lidereau R. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer [J]. Maturitas, 2006,54(4):342-351.
24. van Agthoven T, Sieuwerts AM, Veldscholte J, et al. CITED2 and NCOR2 in anti-oe strogen resistance and progression of breast cancer [J]. Br J Cancer, 2009,101(11):1824-1832.
25. Fleming FJ, Myers E, Kelly G, et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 [J]. J Clin Pathol, 2004,57 (10):1069-1074.
26. Thiery JP, Acloque H, Huang RY, et al. Epithelial-m esenchymal transitions in development and disease [J]. Cell, 2009,139(5): 871-890.
27. Voulgari A, Pintzas A. Epithelial-m esenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic [J]. Biochim Biophys Acta, 2009,1796(2):75-90.
28. Hiscox S, Jiang WG, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT-lik e behaviour and involves modulation of beta-ca tenin phosphorylation [J]. Int J Cancer, 2006,118(2):290-301.
29. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-al pha [J]. Mol Endocrinol, 2007,21(12):2907-2918.
30. Goessl C, Krause H, Muller M, et al. Fluorescent methylation- specific polymerase chain reaction for DNA-ba sed detection of prostate cancer in bodily fluids [J]. Cancer Res, 2000,60(21): 5941-5945.
31. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells [J]. Hum Mol Genet, 1999,8(3):459-470.
32. Brunner AL, Johnson DS, Kim SW, et al. Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver [J]. Genome Res, 2009,19(6):1044-1056.
33. Meissner A, Mikkelsen TS, Gu H, et al. Genome-sc ale DNA methylation maps of pluripotent and differentiated cells [J]. Nature, 2008,454(7205):766-770.
34. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high- throughput analysis of DNA methylation patterns by base- specific cleavage and mass spectrometry [J]. Proc Natl Acad Sci U S A, 2005,102(44):15785-15790.
35. Weber M, Davies JJ, Wittig D, et al. Chromosome-w ide and promoter-sp ecific analyses identify sites of differential DNA methylation in normal and transformed human cells [J]. Nat Genet, 2005,37(8):853-862.
36. Rauch T, Li H, Wu X, et al. MIRA-as sisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain- containing genes in lung cancer cells [J]. Cancer Res, 2006,66 (16):7939-7947.
37. Eads CA, Danenberg KD, Kawakami K, et al. Methylight: a high-th roughput assay to measure DNA methylation [J]. Nucleic Acids Res, 2000,28(8):E32.
38. Khulan B, Thompson RF, Ye K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay [J]. Genome Res, 2006,16(8):1046-1055.
39. Irizarry RA, Ladd-Acosta C, Carvalho B, et al. Comprehensive high-th roughput arrays for relative methylation (CHARM) [J]. Genome Res, 2008,18(5):780-790.
40. Down TA, Rakyan VK, Turner DJ, et al. A Bayesian deconvolution strategy for immunoprecipitation-ba sed DNA methylome analysis [J]. Nat Biotechnol, 2008,26(7):779-785.
41. Ball MP, Li JB, Gao Y, et al. Targeted and genome-sc ale strategies reveal gene-bo dy methylation signatures in human cells [J]. Nat Biotechnol, 2009,27(4):361-368.
42. Laird PW. Principles and challenges of genomewide DNA methylation analysis [J]. Nat Rev Genet, 2010,11(3):191-203.
43. Zuo T, Tycko B, Liu TM, et al. Methods in DNA methylation profiling [J]. Epigenomics, 2009,1(2):331-345.
44. Cheng AS, Culhane AC, Chan MW, et al. Epithelial progeny of estrogen-ex posed breast progenitor cells display a cancer-lik e methylome [J]. Cancer Res, 2008,68(6):1786-1796.
45. Korshunova Y, Maloney RK, Lakey N, et al. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-as sociated cytosine-m ethylation patterns obtained from tissue and serum DNA [J]. Genome Res, 2008,18(1):19-29.
46. Sharma SV, Lee DY, Li B, et al. A chromatin-m ediated reversible drug-to lerant state in cancer cell subpopulations [J]. Cell, 2010,141(1):69-80.